Amwell reported a slight increase in revenue and an expansion of gross margins, but experienced a decrease in total visits. The company is adjusting its visit forecast downwards due to the resurgence of mask mandates and other factors related to the COVID-Delta variant.
Revenue increased 5% over last quarter to $60.2 million.
Gross margins increased 600 bps to 44% of revenue versus 38% last quarter.
Total visits decreased to 1.3 million compared to 1.6 million last quarter.
The company is adjusting down its visit forecast for the remainder of the year.
For 2021, Amwell is adjusting their previous visits outlook to account for changes related to COVID-Delta variant and now expects revenue between $252 and $262 million and Adjusted EBITDA between ($154) and ($146) million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance